Locus Pharmaceuticals' mission is discovering and developing drug treatments using a technology platform that integrates virtual drug design, medicinal chemistry, and biology. Through its Ansaris division the company researches small molecule treatments for a number of illnesses including HIV, cancer, and inflammatory conditions such as arthritis. The company aims to develop drug candidates in-house and partner with other drugmakers to co-develop drugs. Locus counts Novartis Institute of Biomedical Research and Ono Pharmaceuticals among its partners. The privately-held company is led by president Joan Lau. Investors include Norvartis Bioventures and founding investor, Prism Venture Partners.

Abaxis was founded in 1989 and is headquartered in Union City, California. Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements in the medical and veterinarian markets worldwide. Its products include Point-Of-Care Blood Chemistry Analyzer, which performs a panel of 14 tests on human patients and 13 tests on veterinary patients marketed under the Piccolo xpress and Piccolo Classic names in the human medical market and under the VetScan VS2 and VetScan Classic names in the veterinary market. The company's products also include Reagent Discs that handle various technical steps of blood chemistry testing automatically; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, which offer blood count analysis for veterinary applications. In addition, its products comprise VetScan VSpro that assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluation of disseminated intravascular disease, hepatic disease and monitoring therapy, and progression of disease states; and VetScan Canine Heartworm Rapid Test, a test for the detection of dirofilaria immitis in canine whole blood, serum, or plasma. Further, Abaxis's products consist of Orbos Discrete Lyophilization Process, which allows the production of active chemical ingredient in the form of a soluble bead, as well as involves in flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The company markets and sells its products through a direct sales force in the United States and through independent distributors.

GeoPharma, Inc. was founded in 1985 and is headquartered in Largo, Florida. GeoPharma, Inc. is engaged in manufacturing, packaging and distributing private label dietary supplements, generic drugs, and health and beauty products under six of its companies, Innovative Health Products, Inc., Libi Labs, Belcher Pharmaceuticals, Inc., American Antibiotics, LLC and EZ-Med. Innovative Health Products and Libi Labs specialize in the development and manufacture of a range of nutritional supplements and cosmeceuticals. Its subsidiaries include Belcher Pharmaceuticals, Inc., Go2PBM Services, Inc., IHP Marketing, Inc., Breakthrough Marketing, Inc., Belcher Capital Corporation, American Antibiotics, LLC, Libi Labs, Inc., EZ-Med Company (EZ-Med) and Dynamic Health Products, Inc. Effective March 31, 2009, the Company discontinued its Distribution segment, which includes Breakthrough Engineered Nutrition.

Cephalon, Inc. was founded in 1987 and is headquartered in Frazer, Pennsylvania. Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The company's pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa.

Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection. Its pipeline includes clinical and pre-clinical product candidates with mechanisms of action and novel chemical structures. The company's product candidates in clinical development include Azixa (MPC-6827), which is under Phase II clinical trial for the treatment of glioblastoma multiforme and metastatic melanoma; MPC-4326 for HIV-1 infection under Phase IIb clinical trial; and MPC-3100, a Phase I clinical trial product candidate for cancer treatment. Its products in preclinical programs comprise MPI-443803, an orally available, brain penetrant, microtubule destabilizing agent for the treatment of cancer; and MPI-461359, an orally available maturation inhibitor for the treatment of HIV-1 infection, as well as MPI-479605 for the treatment of cancer. The company also offers ProNet, a proprietary database of protein-protein interactions, which encompasses interactions between approximately 10 million protein fragments constructed from various organ tissues, including heart, brain, kidney, liver, breast, and prostate. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah.

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens®.Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.

Bilcare, Inc., formerly ProClinical Pharmaceutical Services, is in favor of pharma. Bilcare, Inc. company, which also operates as Bilcare Global Clinical Services, is the American arm of parent company Bilcare Ltd. Its aim is to help pharmaceutical companies prepare for and conduct clinical trials. Bilcare's offerings include a wide range of analytical research, formulation development, manufacturing, and packaging and labeling of clinical supplies. Logistics services include the storage, distribution, reconciliation, and destruction of clinical trial supplies and investigational medicines. Its services encompass all levels of pharmaceutical drug trials.

Naturewell, Incorporated does not have significant operations. Naturewell company intends to seek business opportunities, including an acquisition or merger with an operating business. Previously, it engaged in the research and development of proprietary healthcare products for various conditions, which comprise primary migraine medication, MIGRASPRAY. Naturewell company is based in San Diego, California.

BioVex Group has developed a virus-containing vaccine which works to prevent and combat certain types of cancer and chronic infectious diseases. The company's lead product, OncoVEX, makes use of an altered virus to attack solid tumor cells but leave healthy cells intact. OncoVEX has shown promise in treating metastatic melanoma and the company has plans to vex other cancers such as pancreatic and colo-rectal cancers. After a brief stint as a publicly-traded company, in 2007 BioVex was taken private by a group of investors led by health science-oriented Triathlon Medical Ventures.

USANA Health Sciences was founded in 1992 and is headquartered in Salt Lake City, Utah. USANA Health Sciences, Inc. develops, manufactures, and sells nutritional and personal care products. The company offers two product lines, USANA Nutritionals and Sense. The USANA Nutritionals product line consists of essentials, which include vitamin and mineral supplements that provide a foundation of nutrition for various age groups; optimizers, which are targeted supplements that support cardiovascular health, skeletal/structural health, and digestive health; and macro-optimizers comprising low-glycemic functional foods and other related products. The Sense product line includes personal care products that support healthy skin and hair. Products in this line consist of perfecting essence, gentle daily cleanser, hydrating toner, daytime protective emulsion, eye nourisher, night renewal, serum intensive, rice bran polisher, creme masque, revitalizing shampoo, nourishing conditioner, firming body nourisher, energizing shower gel, and intensive hand therapy. USANA Health Sciences also provides resource materials and sales tools, including product brochures and business forms, as well as sells reprints of other commercial publications. The company distributes its products through network marketing in the United States, Canada, Mexico, Australia, New Zealand, Singapore, Malaysia, Hong Kong, Taiwan, Japan, South Korea, the United Kingdom, and the Netherlands.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.